Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ADC Cytotoxic Payloads and Warheads Market Size, Share, Trends, and Forecast to 2035 | Precision Oncology and Next-Generation ADCs Unlock USD 469.3 Million OpportunityPrioritize topoisomerase inhibitors, clinical ADCs, capacity expansion and strategic partnerships to capture rising precision oncology demand.
- Biotech Boom Fuels Clinical Lab Evolution as Global IVD Medical Services Market Adapts to the Genomic ShiftExtensive report evaluates the impact of advanced molecular diagnostics, changing U.S. Medicare fee schedules, and the "genetic blizzard" on hospital and laboratory testing demand.
- Germany Precision Oncology Diagnostics Market Size, Share, Trends, and Forecast to 2035 - NGS-based Panels and Liquid Biopsies Drive 15% CAGR Toward USD 5.18 Billion"Germany Precision Oncology Diagnostics Market by Test Type (Companion Diagnostics, NGS-based Panels, Liquid Biopsy Tests, IHC / FISH-based Tests, PCR-based Tests), Type of Technology, Disease Indication, Sample Type, End User and Regional Hub - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
- China Next-Generation Antibody-Drug Conjugate (ADC) Innovation Market Forecast to 2035 | USD 1.33 Billion Opportunity Fueled by Global Licensing and Bispecific ADC GrowthBenchmark China-origin ADC assets, licensing partners and innovation hubs to guide market-entry, capital allocation and portfolio stress-testing
- AgeReverse RESURGE Now Available to U.S. Consumers on AmazonBoca Raton, Florida Friday Oct 16, 2026 @ 5:00 AM Eastern — AgeReverse, a Canadian longevity company focused on healthy aging and cellular vitality, today announced that its flagship RESURGE formulation is now available to U.S. consumers on Amazon, marking another significant step in the company’s expansion into the American market. The Amazon launch follows a series of U.S. expansion initiatives for AgeReverse, including the company’s recent participation in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida. With RESURGE now available through one of the country’s largest online marketplaces, AgeReverse is expanding consumer access while continuing to introduce its broader science-first approach to healthy aging. “Making RESURGE available on Amazon is an important milestone for AgeReverse because it gives consumers across the United States convenient access to our first product in the market,” said Kubi Turkmen, Founder and CEO of AgeReverse. “We are building AgeReverse around a comprehensive view of healthy aging, and RESURGE represents the internal wellness component of that larger vision.” AgeReverse developed RESURGE around the scientific concept of the 12 Hallmarks of Aging, a framework used by researchers to describe interconnected biological processes associated with aging. Rather than focusing on a single ingredient or isolated wellness benefit, the company designed RESURGE as a multi-ingredient formulation intended to support multiple aspects of healthy aging and everyday wellness. The 90-capsule formulation combines ingredients including NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract and Noni Berry into a simplified three-capsule daily regimen. Key features and benefits of RESURGE include: Designed to support all 12 Hallmarks of Aging through a comprehensive longevity-focused formulation Combines ingredients including NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract, and Noni Berry Provides antioxidant support to help protect cells from oxidative stress and free radical damage Supports nutrient metabolism and overall cellular health Helps support cardiovascular health and immune system function Supports collagen formation, connective tissue development, and skin quality Helps maintain healthy joints, cartilage, bones, gums, and connective tissue Includes herbal ingredients traditionally used as capillary and blood vessel protectants Consolidates what the company describes as 15+ supplement protocols into a simplified 3-capsule daily routine Manufactured in GMP-certified facilities in Ontario, Canada using vegan capsules Registered as a Natural Health Product with Health Canada The Amazon availability also advances a broader AgeReverse strategy that extends beyond nutritional wellness. The company is developing a complete range of healthy aging products and technologies intended to address both internal wellness and external skin aging. The planned AgeReverse product range includes a Bioage Test, daily skincare products developed around the 12 Hallmarks of Aging, professional mesotherapy products for the medical aesthetics and medspa markets, and non-invasive mesotherapy technology designed to deliver skincare formulations without needles. “Our vision has always extended beyond one product,” Turkmen added. “We believe healthy aging should be approached from both inside and outside the body. RESURGE gives U.S. consumers an introduction to that philosophy, and Amazon gives us an important channel for building awareness and accessibility as the AgeReverse product range grows.” AgeReverse is positioning its expanding portfolio around a science-first philosophy aimed at men and women interested in longevity, healthy aging, cellular wellness and maintaining vitality as they age. The company plans to serve both consumers and professionals in the medical aesthetics market as additional products are introduced. RESURGE is now available to U.S. consumers on Amazon. AgeReverse plans to continue expanding its product range and U.S. presence as additional products become available. Visit the AgeReverse Website and follow the company on Instagram and LinkedIn. About AgeReverse AgeReverse is a Canada-based longevity wellness company focused on developing science-driven products designed to support healthy aging and cellular vitality. Founded by Kubi Turkmen, who has more than 30 years of experience in anti-aging innovation, the company’s approach combines longevity research, telomere science, and wellness innovation to create comprehensive healthy aging solutions. The company’s expanding AgeReverse platform includes longevity supplements and other wellness technologies designed to support multiple biological pathways associated with aging and long-term vitality. Products are manufactured in GMP-certified facilities in Ontario, Canada. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
- Creative BioTherapeutics Named 2026 Prix Galien USA Best Startup Nominee for Work Advancing CBT300Recognition marks a new chapter for the oncology-focused biotechnology company as it continues development of its investigational biologic candidate targeting mechanisms associated with cancer recurrence and treatment resistance.
- Friendly Recovery Center Publishes New Resource on Low Libido and How Therapy Can Improve IntimacyEducational article explores the emotional, physical, and relationship factors affecting sexual desire and how therapeutic support may help improve intimacy.
- Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of HematologyInnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of orelabrutinib, its novel BTK inhibitor, have been selected for oral presentations at the 88th Annual Meeting of the Japanese Society of Hematology (JSH 2026).
- Microbiotica Raises £36 Million ($48 Million) in Series C Financing to Advance Pipeline into Phase 2 Clinical DevelopmentMicrobiotica, a clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines, today announces the first close of a £36 million ($48 million) Series C financing.
- FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)Companies: Roche HoldingBasel, 16 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. Enspryng can be administered by a person living with TED or a caregiver following training from a healthcare provider.1
- GenentechFDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile, regardless of TED activity or duration Enspryng (satralizumab-mwge) represents an important advance for peo
- Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal CancerExtending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer